Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales

Zevra Therapeutics

05/08/2026 22:10

Overview
U.S. rare disease drugmaker's Q2 revenue rose 53% yr/yr, beating analyst expectations
Q2 net income fell sharply from prior yr, which included one-time gains
Operating expenses declined yr/yr, mainly due to lower SG&A costs

Outlook
Company expects to continue engagement with FDA on celiprolol development in H2 2026
Company says available financial resources are sufficient to execute on strategic priorities
Company pursuing European approval for arimoclomol; global Expanded Access Program remains active

Result Drivers
MIPLYFFA SALES - Majority of Q2 revenue driven by $30.2 mln in MIPLYFFA sales for Niemann-Pick disease type C
EXPANDED ACCESS PROGRAM - $9.0 mln in net reimbursements from global Expanded Access Program contributed to revenue

Company press release: ID:nGNX71Bl73

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$39.66 mln
$33.88 mln (9 Analysts)
Q2 Net Income
 
$8.75 mln
 
Q2 Income from Operations
 
$16.78 mln
 
Q2 Operating Expenses
 
-$21.05 mln
 
Q2 Pretax Profit
 
$12.79 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Zevra Therapeutics Inc is $24.50, about 132.9% above its August 4 closing price of $10.52
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Aug 4 - Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Aug 5 - BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance
Aug 5 - United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weakness

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)